| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/15/2004 | US20040071711 Imaging, diagnosis and treatment of disease |
| 04/15/2004 | US20040071710 Human monoclonal antibody against hepatitis c virus e2 glycoprotein |
| 04/15/2004 | US20040071701 Nerve growth factor antagonist for treating pain caused by physiological disorder, no side effects |
| 04/15/2004 | US20040071697 Reducing epithelial toxicity during cancer therapy |
| 04/15/2004 | US20040071686 Treatment of alpha-galactosidase A deficiency |
| 04/15/2004 | CA2503674A1 Quinazolin-4-one derivatives |
| 04/15/2004 | CA2501017A1 Remedies |
| 04/15/2004 | CA2500904A1 Composition containing eosinophil cationic protein |
| 04/15/2004 | CA2500869A1 Spiro compounds, medicinal compositions containing the same and intermediates of the compounds |
| 04/15/2004 | CA2500527A1 Remedies |
| 04/15/2004 | CA2500413A1 Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity |
| 04/15/2004 | CA2498659A1 Condensed palatinose in hydrogenated form |
| 04/14/2004 | EP1408119A1 Method of screening abc protein promoter/inhibitor |
| 04/14/2004 | EP1408117A1 Glycoprotein and process for producing the same |
| 04/14/2004 | EP1408112A1 MONOCLONAL ANTIBODY BINDING TO MT4−MMP CATALYTIC DOMAIN |
| 04/14/2004 | EP1408109A1 Novel transformed cells, method of screening antiaging agent and antiaging agents |
| 04/14/2004 | EP1408045A1 Novel galactosylceramide analogs and beta-glucocerebrosidase activators,external skin preparations and method of activating beta-glucocerebrosidase using the analogs |
| 04/14/2004 | EP1408042A1 Novel isoxazolopyridone derivatives and use thereof |
| 04/14/2004 | EP1408038A2 Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase |
| 04/14/2004 | EP1408033A1 Dibenzocycloheptene compound |
| 04/14/2004 | EP1407785A1 Medicinal compositions |
| 04/14/2004 | EP1407783A1 Remedies for hernia |
| 04/14/2004 | EP1407782A1 Preventives/remedies for organ functional disorders and organ dysfunction |
| 04/14/2004 | EP1407770A1 Tgf-beta superfamily production/secretion promoter |
| 04/14/2004 | EP1407768A2 The potassium channel opener retigabine for the treatment of diseases |
| 04/14/2004 | EP1407261A1 In vivo bioreactors |
| 04/14/2004 | EP1407044A2 Rna interference mediating small rna molecules |
| 04/14/2004 | EP1407043A2 Gamma-secretase in vitro screening assay |
| 04/14/2004 | EP1407013A1 Mutations in ion channels |
| 04/14/2004 | EP1407010A1 Regulation of human aminopeptidase n |
| 04/14/2004 | EP1406928A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 04/14/2004 | EP1406922A2 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 04/14/2004 | EP1406915A2 Antisense modulation of transforming growth factor beta receptor ii expression |
| 04/14/2004 | EP1406914A2 Porphyrin derivatives for photodynamic therapy |
| 04/14/2004 | EP1406908A1 Morpholine-bridged pyrazolopyridine derivatives |
| 04/14/2004 | EP1406906A1 Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| 04/14/2004 | EP1406902A1 Hexahydroazepino(4,5-g)indoles and indolines as 5-ht receptor ligands |
| 04/14/2004 | EP1406901A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease |
| 04/14/2004 | EP1406899A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 04/14/2004 | EP1406898A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 04/14/2004 | EP1406897A2 Compounds |
| 04/14/2004 | EP1406894A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 04/14/2004 | EP1406893A1 Pyrrolidine bicyclic compounds |
| 04/14/2004 | EP1406891A1 Thiochromenones used to combat painful conditions and neurodegenerative diseases |
| 04/14/2004 | EP1406889A2 Interaction inhibitors of tcf-4 with beta-catenin |
| 04/14/2004 | EP1406884A1 Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
| 04/14/2004 | EP1406883A1 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3) |
| 04/14/2004 | EP1406880A1 Crystalline thiazine oxazolidinones |
| 04/14/2004 | EP1406878A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 04/14/2004 | EP1406877A1 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 04/14/2004 | EP1406876A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| 04/14/2004 | EP1406875A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/14/2004 | EP1406873A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 04/14/2004 | EP1406872A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 04/14/2004 | EP1406869A1 Taxol enhancer compounds |
| 04/14/2004 | EP1406867A2 Thiolalkyl benzoic acid derivatives |
| 04/14/2004 | EP1406866A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 04/14/2004 | EP1406859A1 Substituted 4-aminocyclohexanol derivatives |
| 04/14/2004 | EP1406700A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 04/14/2004 | EP1406698A2 Lipoxin analogs as novel inhibitors of angiogenesis |
| 04/14/2004 | EP1406696A1 Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease |
| 04/14/2004 | EP1406667A2 METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS |
| 04/14/2004 | EP1406664A2 Targeting chemical compounds to cells |
| 04/14/2004 | EP1406660A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 04/14/2004 | EP1406653A2 T cell regulatory genes and methods of use thereof |
| 04/14/2004 | EP1406650A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 04/14/2004 | EP1406639A2 Method for enhancing the effectiveness of cancer therapies |
| 04/14/2004 | EP1406637A2 Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative |
| 04/14/2004 | EP1406634A1 Combination of drospirenone and an estrogen sulphamate for hrt |
| 04/14/2004 | EP1406633A1 Enhanced drug delivery in transdermal systems |
| 04/14/2004 | EP1406632A2 Substituted 3-aryl-5-aryl- 1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 04/14/2004 | EP1406629A1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump |
| 04/14/2004 | EP1406628A1 Tetrahydroquinoline derivatives |
| 04/14/2004 | EP1406626A2 Sulphonyl aryl hydroxamates and their use as mmp inhibitors |
| 04/14/2004 | EP1406625A1 A PROCESS FOR PREPARING PAROXETINE HCl WHICH LIMITS FORMATION OF PINK COLORED COMPOUNDS |
| 04/14/2004 | EP1406620A1 Vinyl phenyl derivatives as glk activators |
| 04/14/2004 | EP1406618A2 Use of nk-1 receptor antagonists with pyridinic structure for the treatment of brain, spinal or nerve injury |
| 04/14/2004 | EP1406617A1 Diaminediols for the treatment of alzheimer's disease |
| 04/14/2004 | EP1406616A1 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same |
| 04/14/2004 | EP1406615A1 Kinase inhibitors and the use thereof |
| 04/14/2004 | EP1406613A1 Organic nitrate-based compounds for the treatment of vasculopathies |
| 04/14/2004 | EP1406611A2 Method for treating fibrotic diseases or other indications |
| 04/14/2004 | EP1406609A2 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 04/14/2004 | EP1406608A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use |
| 04/14/2004 | EP1406602A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 04/14/2004 | EP1406600A1 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 04/14/2004 | EP1375465A9 Cyclooctanone derivative and cyclodecanone derivative, and use thereof |
| 04/14/2004 | EP1301522A4 Novel compounds and methods |
| 04/14/2004 | EP1214312B1 5-aminoalkyl and 5-aminocarbonyl substituted indoles |
| 04/14/2004 | EP1214299B1 Muscarinic antagonists |
| 04/14/2004 | EP1202994B1 New compounds |
| 04/14/2004 | EP1200419B1 Aminothiazole derivatives and their use as crf receptor ligands |
| 04/14/2004 | EP1171440B1 Substituted-3-cyano-[1.7],[1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases |
| 04/14/2004 | EP1156054B1 Drugs containing phosphoric acid derivatives as the active ingredient |
| 04/14/2004 | EP1073641B1 New substituted amides, their production and their use |
| 04/14/2004 | EP1073334A4 Serotonin potentiation by oleamide analogs |
| 04/14/2004 | EP1062206B1 Amino anthracyclinone derivatives and their use in the treatment of amyloidosis |
| 04/14/2004 | EP1042315B1 Cyclic imide-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic and immunosuppressive agents |
| 04/14/2004 | EP0979240B1 Serine protease inhibitors |
| 04/14/2004 | EP0935465B1 Novel substituted imidazole compounds |